LWLinda Myrin Westesson

Linda Myrin Westesson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Linda Myrin Westesson has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Olsson

    Department of Medicine Region Västra Götaland Sahlgrenska University Hospital Gothenburg Sweden

    4 shared publications
  • Anna Olsson

    Sahlgrenska University Hospital

    2 shared publications
  • Anna Paganini

    Department of Plastic Surgery, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Plastic Surgery, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden; Department of Diagnostics, Acute and Critical Care, Institute of Health and Care Sciences, Sahlgrenska Academy at the University of Gothenburg, University of Gothenburg, Gothenburg, Sweden

    2 shared publications
  • Emma Engman Grahn

    Region Skåne Skåne University Hospital Department of Hematology Oncology and Medical physics Malmö Sweden

    2 shared publications
  • Emma Hansson

    Department of Plastic Surgery, Institute of Clinical Sciences, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Plastic Surgery, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden

    2 shared publications
  • F. Baghaei

    Coagulation Centre, Department of Medicine/Haematology and Coagulation Disorders, Sahlgrenska University Hospital, Gothenburg, Sweden

    2 shared publications

Latest Publications

  • Open Access

    Living With Acquired Haemophilia: Patients’ and Relatives’ Experiences - A Single-Centre Study

    by Amanda Jonsson, Susanne Ahlstedt Karlsson, Anna Olsson, Linda Myrin-Westesson

    Background: Acquired haemophilia (AH) is a rare and potentially life-threatening bleeding disorder characterised by sudden onset, unpredictable bleeding, and complex treatment. Despite its severity, little is known about how patients and their relatives experience life with the illness. Aim: To describe the experiences of daily life among patients with AH and their close relatives. Methods: A qualitative study using thematic analysis was conducted. Interviews were performed with 12 patients diagnosed with AH and six relatives recruited from one European Haemophilia Comprehensive Care Centre (EHCCC). Data were analysed inductively following Nowell’s six-phase approach. Results: The overarching finding was the experience of loss of control and the subsequent need to regain normality. Three main themes were identified: Experiencing loss of control, Adaptations in everyday life, and Finding strategies to obtain normality. Participants described persistent uncertainty, fear, and unmet informational needs, which contributed to ongoing distress even after clinical recovery. AH disrupted identity, daily routines, and family roles, requiring continuous adaptation. Support from family and healthcare professionals was essential, although participants reported insufficient or delayed support. Strategies to regain control included reframing the illness, gradually rebuilding trust in the body and relying on medical follow-up. Conclusions: This study highlights the impact of AH on both patients and relatives, emphasising the need for improved knowledge, structured support, and greater involvement of relatives in care. Increased contact with the EHCCC may enhance understanding, reduce uncertainty, and thereby strengthen illness management. A more coordinated approach is needed to ensure adequate support throughout the illness trajectory.

  • Open Access

    Perceived experiences of people with severe haemophilia A switching from factor VIII prophylaxis to emicizumab

    by Linda Myrin-Westesson, Anna Olsson

    Introduction: Emicizumab is a humanised, bispecific monoclonal antibody that bridges activated factor (F) IX and FX; it is approved for treatment of people with haemophilia A (PwHA) of all ages, with or without FVIII inhibitors. Qualitative experiences of PwHA switching to non-factor treatments, such as emicizumab, are needed to facilitate shared decision-making (SDM). Aim: This study aimed to describe experiences of switching from FVIII prophylaxis to emicizumab among PwHA. Methods: Participants with severe haemophilia A without FVIII inhibitors from the Swedish cohort of the HemiNorth 2 study (MO42245; EudraCT# 2020-003256-32) were subject to qualitative interviews in 2023, which were analysed through content analysis. Results: Overall, nine participants were interviewed. The analysis revealed three categories: ‘Adapting to a new reality’, ‘A feeling of normality’ and ‘Shattered expectations’. Participants reported that switching from FVIII prophylaxis to emicizumab fostered a feeling of normality, with the disease taking less time and space in their daily lives. The participants also described increased confidence in physical activity, and a newfound hope for the future treatment of haemophilia. However, not all expectations were met, as the disease persisted and still affected daily life. Some participants also reported a lack of information about emicizumab from a patient perspective. Conclusion: The findings convey a sense of normality among PwHA switching to emicizumab, stemming from a reduced disease and treatment burden. The results highlight the gaps in knowledge among PwHA, which can help inform SDM practice and manage expectations when switching to a non-factor treatment.


  • Low bleeding rates after intramuscular Covid‐19 vaccination in patients with haemophilia and von Willebrand disease: Outcome data from the Swedish haemophilia registry

    by Nadine G. Andersson, Hannes Brange, Jan Astermark, Malin Axelsson, Fariba Baghaei, Maria Magnusson, Anna Olsson, Elsa Olsson, Susanna Ranta, Linda Myrin Westesson, et al.

  • Open Access

    Women's experiences of health care providers when choosing flat closure after breast cancer: An interview study

    by Susanne Ahlstedt Karlsson, Linda Myrin Westesson, Emma Hansson, Anna Paganini


  • Open Access

    Women’s decision process when actively choosing to ‘go flat’ after breast cancer: a constructivist grounded theory study

    by Anna Paganini, Linda Myrin Westesson, Emma Hansson, Susanne Ahlstedt Karlsson

    Objective: This study aims to describe a conceptual model that could illuminate the decision process women go through when choosing to go flat on one or both sides due to breast cancer. Methods: A qualitative design, with constructivist grounded theory was used. Eighteen women were individually interviewed, digitally or by telephone, until saturation was reached. Data were analysed using a constant comparative iterative method in accordance with grounded theory. By examining the text data to identify the decision process for going flat and rejecting reconstructive surgery open coding was obtained. As the study proceeded patterns were explored and categories developed into a core category. Results: The overall decision process for women choosing to go flat on one or both sides emerged in three phases: Phase 1, where the women are forced to “Face the cancer”, Phase 2 comprising “Reflections on health and motivation” and Phase 3, described as “Hobson’s choice”. The fundament of the decision process was found in the core category “Establishing and safeguarding the chosen self”. Conclusions: The decision process involved in actively going flat and rejecting reconstructive surgery is founded in the individual woman’s motivations, such as view of femininity and apprehensions about the offered reconstructive surgery.


  • Open Access

    The role of the specialist nurse in comprehensive care for bleeding disorders in Europe: An integrative review

    by Greta Mulders, Nanda Uitslager, Mary Kavanagh, Maj Friberg Birkedal, Gabriella Nicolo, Renester Fenton, Linda Myrin Westesson, The European Association for Haemophilia and Allied Disorders (EAHAD) Nurses Committee

    Introduction: Managing bleeding disorders (BDs) is complex, requiring a comprehensive approach coordinated by a multidisciplinary team (MDT). Haemophilia nurses (HNs) play a central role in the MDT, frequently coordinating care. As novel treatments bring change to the treatment landscape, ongoing education and development is key. However, understanding of the roles and tasks of HNs is lacking.Aim: The EAHAD Nurses Committee sought to identify and describe the roles and tasks of the European HN.Methods: A five‐step integrative review was undertaken, including problem identification, literature search, data evaluation, data synthesis and presentation. Relevant literature published from 2000 to 2022 was identified through database, hand and ancestry searching. Data were captured using extraction forms and thematically analysed.Results: Seven hundred and seventy‐seven articles were identified; 43 were included. Five main roles were identified, with varied and overlapping associated tasks: Educator, Coordinator, Supporter, Treater and Researcher. Tasks related to education, coordination and support were most frequently described. Patient education was often ‘nurse‐led’, though education and coordination roles concerned both patients and health care practitioners (HCPs), within and beyond the MDT. The HN coordinates care and facilitates communication. Long‐term patient care relationships place HNs in a unique position to provide support. Guidelines for HN core competencies have been developed in some countries, but autonomy and practice vary.Conclusion: As the treatment landscape changes, all five main HN roles will be impacted. Despite national variations, this review provides a baseline to anticipate educational needs to enable HNs to continue to fulfil their role.


  • HRQoL and psychosocial aspects of burden on caregivers to children with moderate or severe von Willebrand disease

    by Anna Olsson, Pia Petrini, Emma Engman Grahn, Linda Myrin Westesson

    Introduction: Von Willebrand disease (VWD) is the most widespread congenital bleeding disorder. Caregivers are highly involved in its treatment, and from the time of the child's bleeding diagnosis, they face new demands such as recognition of bleeds and treatment options.Aim: The aim of this study was to assess Health related quality of life (HRQoL) in caregivers of children with moderate and severe VWD in Sweden, and to describe the impact of psychosocial aspects on the burden.Methods: A multicentre, cross‐sectional study. The Short Form 36 Health Survey (SF‐36) was used to assess HRQoL. Caregiver burden was measured using The HEMOphilia associated Caregiver Burden scale (HEMOCAB). Children´s clinical data were collected from the Swedish national registry for bleeding disorders.Results: Seventy caregivers of children with moderate or severe VWD were included. Caregivers of children with moderate VWD scored significantly lower in the mental health domains on SF‐36, compared to matched normative data. Psychosocial aspects that significantly impacted the caregiver burden negatively measured by HEMOCAB total score were: if the caregiver reported that VWD affected their life in general (p = .001), if the child was absent from preschool/school ≥2 day/12 months due to VWD (p = .002) or that VWD had a financial impact on the family (p = .001).Conclusion: This study contributes to knowledge about caregivers’ HRQoL and highlights the situation of caregivers of children with moderate VWD. Furthermore, the caregiver burden was negatively affected by psychosocial aspects. Clinical follow‐ups should include assessment of psychosocial aspects to identify caregivers that are at risk of high burden.


  • Burden on parents of children with moderate or severe von Willebrand disease: The impact of clinical data

    by Linda Myrin Westesson, Pia Petrini, Emma Engman Grahn, Anna Olsson


  • Open Access

    Haemophilia specialist nurses’ perceptions of haemophilia B

    by Steve Chaplin, Maj Friberg Birkedal, Erica Crilly, Simon Fletcher, Sara Garcia, Greta Mulders, Linda Myrin-Westesson, Debra Pollard, Anna Sanigorska, Nanda Uitslager

    Introduction: Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes. Current clinical practice reduces the risk of bleeds, making differences difficult to measure. We surveyed specialist haemophilia nurses to discern their opinions about the impact of haemophilia B compared to haemophilia A. Methods: Between July and September 2020, European and Canadian nurses were invited to complete an online survey (25 questions) about perceptions of management and treatment of haemophilia B. Results: Fifty-nine nurses (46 European, 13 Canadian) completed the survey. Bleeding was reported as different in haemophilia B by 37% of respondents, and treatment as different by over half. Opinions and experience around using extended half-life (EHL) products varied. Self-reported confidence in using EHL products was rated at a mean of 7.1 (range 3–10) with 47% believing these would remain the optimal treatment in 2025. Conclusion: Some nurses believe haemophilia A and B are managed differently. Variations in experience and levels of confidence in the use of EHL products, combined with a belief that these products will remain an optimal treatment for haemophilia B for the next five years, indicates a need for education to promote confidence and competence.